CEO Hanna Sjöström presented at Aktiedagarna in Stockholm on June 10, 2026, sharing an update on the company’s latest advancements following the positive safety results from Neola Medical’s first clinical pilot study in preterm born babies, provided an update on the company’s sharpened strategic focus, U.S. regulatory pathway, and commercial preparations toward market launch.
The ongoing rights issue, with subscription period June 3–17, 2026, is intended to finance Neola Medical’s continued development, regulatory processes and commercial preparations ahead of market launch.
